Pfizer (PFE), BioNTech SE (BNTX) Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioNTech SE (BNTX) Announces 5M Share Proposed Public Offerings of ADSs and Rights Offering
July 21, 2020 8:51 AM EDTBioNTech SE (Nasdaq: BNTX, BioNTech or the Company) announced today the proposed public offerings described below. The completion of the proposed public offerings is subject to market and other factors.
BioNTech announced the commencement of a firm commitment underwritten offering (the Underwritten Offering) of 5,000,000 American Depositary Shares (ADSs), each representing one of its ordinary shares. In connection with the Underwritten Offering, an existing shareholder intends to grant the... More
Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update
July 21, 2020 8:42 AM EDTMorgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.
Risinger await results from BNT162b2(full spike)... More
Mizuho 'Encouraged' by Pfizer (PFE) COVID-19 Vaccine Data
July 20, 2020 10:57 AM EDTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $38.00 price target on Pfizer (NYSE: PFE), citing continued positive progress on its COVID vaccine.
The analyst commented, "We are encouraged by new data from Pfizer and partner BioNTech on the progress they are... More
